Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (DE:ICY)
FRANKFURT:ICY
Holding DE:ICY?
Track your performance easily
ICY Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€47.11 - €78.52
Previous Close€64
Volume0.00
Average Volume (3M)496.00
Market Cap
€12.39B
Enterprise Value€10.73B
Total Cash (Recent Filing)$1.77B
Total Debt (Recent Filing)$32.16M
Price to Earnings (P/E)550.3
Beta>-0.01
Next Earnings
Feb 13, 2025EPS Estimate
€1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding192,650,249
10 Day Avg. Volume23
30 Day Avg. Volume496
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.89
Price to Sales (P/S)3.17
Price to Cash Flow (P/CF)10.40
P/FCF Ratio11.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.63
Enterprise Value/Gross Profit3.12
Enterprise Value/Ebitda29.60
Forecast
1Y Price Target
€75.38Price Target Upside17.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Incyte News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsTafa provided an impressive outcome in its trials.
EarningsJakafi and Opzelura sales beat contribute to an overall top-line beat and guidance raise.
Product DevelopmentThe company expects three near-term launches that could reach over $800 million in incremental revenues by 2029.
Bears Say
Financial ConcernsWith a looming $3B patent cliff and a $1.8B cash position, shares are perceived as fairly valued until a significant acquisition or successful late-stage clinical data emerges.
Growth And Revenue IssuesJakafi's growth is slowing down despite efforts to expand its indications in PV and GVHD, raising concerns about sustaining revenue momentum.
Pipeline ChallengesThe discontinuation of zilurgisertib, the ALK2 inhibitor, highlights ongoing struggles in the development pipeline, adding to a growing list of setbacks.
---
ICY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was €47.11 and its highest was €78.52 in the past 12 months.
What is Incyte Corp’s market cap?
Currently, no data Available
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Feb 13, 2025 which is in 54 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Oct 29, 2024. The company reported €1.019 earnings per share for the quarter, beating the consensus estimate of €1.001 by €0.018.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is €1.41.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 192,650,250 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of €1.019 in its last earnings report, beating expectations of €1.001. Following the earnings report the stock price went up 8.997%.
Which hedge fund is a major shareholder of Incyte Corp?
Among the largest hedge funds holding Incyte Corp’s share is Baker Bros Advisors LP. It holds Incyte Corp’s shares valued at 2B.
---
Incyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€75.38 (17.79% Upside)
€75.38 (17.79% Upside)
Blogger Sentiment
Bullish
DE:ICY Sentiment 90%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $839.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.29%
12-Months-Change
Fundamentals
Return on Equity
0.80%
Trailing 12-Months
Asset Growth
-21.54%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
---
ICY Company Deck
---
ICY Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance by Incyte, with significant revenue growth and key product approvals. The pipeline is progressing well with several promising developments. However, there were notable increases in R&D and SG&A expenses. Overall, the positive aspects outweigh the negatives, indicating a strong quarter for Incyte.Read More>---
ICY Revenue Breakdown
85.65% Product revenues, net
14.16% Product royalty revenues
0.19% Milestone and contract revenues
---
ICY Stock 12 Month Forecast
Average Price Target
€75.38
▲(17.79% Upside)
Technical Analysis
Incyte
―
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Exelixis
―
Vertex Pharmaceuticals
―
Best Analysts Covering ICY
1 Year
1 Year Success Rate
23/31 ratings generated profit
1 Year Average Return
+10.52%
reiterated a buy rating 9 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 74.19% of your transactions generating a profit, with an average return of +10.52% per trade.
---